FTC Urged To Investigate AbbVie’s IP Strategy On Humira

US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023

 
• By Dave Wallace
  
Hourglass Delay Stop Time
The FTC has been asked to investigate AbbVie over delays to Humira biosimilars • Source: Alamy

More from Biosimilars

More from Products